Covidien Receives FDA Approval For Fentanyl Transdermal System Patch

Links shared publicly online about this topic.

509
total visits

Covidien Receives FDA Approval For Fentanyl Transdermal System Patch

Covidien (NYSE: COV), a leading global provider of healthcare products, announced that Mallinckrodt Inc., a Covidien company, has received U.S. Food and Drug Administration (FDA) approval of its A

View full resource at medicalnewstoday.com

Tags: Pain, Cancer Pain Medication, Diet and Nutrition, Drug, Healthcare, FDA, Duragesic, Actiq

Most Recently Shared on February 13, 2011 at 5:05 pm By:

MNT Drug Approvals

Covidien Receives FDA Approval For Fentanyl Transdermal System Patch http://mnt.to/3R6H #regulatory

1 year ago...

Retweet

Favorite

Also Shared By:

MNT Pain News

Covidien Receives FDA Approval For Fentanyl Transdermal System Patch - QualityPoint Technologies

qualitypointtech.net — “Covidien (NYSE: COV), a leading global provider of healthcare products, announced that Mallinckrodt Inc., a Covidien company, has received U.S. Food and Drug Administration (FDA) approval of its Abbreviated New Drug Application (ANDA) for its Fentanyl Transdermal System (FTS) patch. Covidien is the largest supplier of controlled pain medications in the United States based on number of prescriptions. Covidien's FTS is a generic alternative to the branded DURAGESIC® patch...” View full resource at qualitypointtech.net